Trump nominates White House adviser Overton as next FDA commissioner
Seeking Alpha News (Wed, 19-Aug 12:19 PM ET)
Alnylam initiated an outperform at BMO on RNAi pipeline
Seeking Alpha News (Wed, 19-Aug 12:02 PM ET)
Trump expected to nominate White House aide Heidi Overton as FDA commissioner
Seeking Alpha News (Wed, 19-Aug 1:26 AM ET)
Enliven a new outperform at Barclays on potential of CML asset
Seeking Alpha News (Tue, 18-Aug 10:37 AM ET)
3 Dividend ETFs Crushing the S&P 500 in 2026
TipRanks (Mon, 17-Aug 8:52 AM ET)
The Quest to Repair What Multiple Sclerosis Takes Away
Globe Newswire (Wed, 24-Jun 8:30 AM ET)
Market Chameleon (Fri, 27-Feb 4:23 AM ET)
Here's what history shows about NVS past earnings run-ups
Market Chameleon (Fri, 11-Jul 7:42 AM ET)
NVS Pre-Earnings History Points to a Sharp Rally
Market Chameleon (Wed, 23-Apr 6:15 AM ET)
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Novartis Ag trades on the NYSE stock market under the symbol NVS.
As of August 19, 2026, NVS stock price climbed to $160.31 with 2,228,772 million shares trading.
NVS has a beta of 0.12, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.00 to the broad based SPY ETF.
NVS has a market cap of $304.70 billion. This is considered a Mega Cap stock.
Last quarter Novartis Ag reported $14 billion in Revenue and $2.41 earnings per share. This beat revenue expectation by $284 million and exceeded earnings estimates by $.25.
In the last 3 years, NVS traded as high as $170.46 and as low as $92.19.
The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, DFAI, DFIC, AVDE, PPH.
NVS has outperformed the market in the last year with a price return of +33.1% while the SPY ETF gained +20.7%. NVS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +7.5% and +4.6%, respectively, while the SPY returned +4.4% and -0.3%, respectively.
NVS support price is $152.48 and resistance is $156.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.